iwCLL 2017 | What should we be focusing on in CLL research?
Stephan Stilgenbauer
• 11 Aug 2017
Stephan Stilgenbauer, MD, from Ulm University, Ulm, Germany, provides us with an insight into the importance of matching optimal therapeutic regimens to individual patients with chronic lymphocytic leukemia (CLL), as the disease is highly heterogenous. He adds that it important to focus research on CLL mutations, including the 17p deletion and p53, which guide treatment away from chemotherapy. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
